Unsere neueste Arbeit, gerade erschienen in #Nature zeigt, dass unser Immunsystem dreimal das Spike Protein gesehen haben muss um eine qualitativ hochwertige Immunantwort aufzubauen. Wichtig: eine Durchbruchsinfektion muss da auch anerkannt werden!

Blaming people with ALD for their condition is central to the @stigma of ALD #LiverTwitter. Understanding how stigma works is the way out - Journal of Hepatology EASLnews EASL Education Georg Schomerus Aleksander Krag Ahmed Elsharkawy Ramon Bataller Patrick Corrigan

Interesting. Number of highly cited scientists/engineers by country among top 100K most cited in the world and those numbers normalized by size of country. (Source: elsevier.digitalcommonsdata.com/datasets/btchx…)

Should we continue NUC treatment when HBsAg levels have become low? - Randomised STOP NUC trial results are published today 28% HBsAg loss if HBsAg levels <1,000 IU/mL 40.5% SVR Re-therapy 13.9% Journal of Hepatology EASLnews #livertwitter EASL Education my_UEG authors.elsevier.com/sd/article/S01…

🔆Brand spanking new🔆: Enjoy reading how stopping antiviral treatment may induce HBsAg loss in patients with low HBsAg levels. A multicenter randomized-controlled trial of nucleos(t)ide analogue ce... sciencedirect.com/science/articl…

From the Editor’s Desk... journal-of-hepatology.eu/article/S0168-…

Thanks to Zeljko Antic, Anke Bergmann, Konstantin Riege and Steve Hoffmann for this great collaboration!

Immune checkpoint inhibition (ICI) in current systemic therapies for h... sciencedirect.com/science/articl…

Meet Giants 💪🏻in #NITs ⁦Naim Alkhouri⁩ ⁦Rohit Loomba⁩ ⁦Mazen Noureddin, MD, MHSc⁩ ⁦Maru Rinella MD⁩ ⁦Alina Allen⁩ #Arun Sanyal ⁦VCU⁩ ⁦Quentin M. Anstee⁩ #Laurent Castera #TLMdx ⁦AASLD⁩ ➡️ let’s solve the NIT challenge in MASH trials 🔌🔋⚡️

I just viewed this new Answers in CME activity on hepatocellular carcinoma with Dr. Galle. Check it out! #CME #Oncology answersincme.com/psocial/share/…